Molbio Diagnostics IPO GMP Today and a Deep Forensic Analysis | India's Financial Intelligence Terminal

Molbio Diagnostics

MAINBOARD IPO · BSE · 📅 UPCOMING

FINMINUTES IPO SCORE 65/100 provisional · updates with subscription

₹768–807

Price Band

Issue ₹940 cr · Lot 18

FinMinutes Deep Business Model & Edge

Molbio Diagnostics Limited is an innovative point-of-care (POC) diagnostics company that designs, develops, and manufactures portable, real-time PCR platforms and diagnostic test kits. The company generates recurring revenue primarily through the sale of its 'Truenat' test kits and devices to public healthcare programs, private laboratories, and hospitals.

What this company actually does — full breakdown ▾

Incorporated in 2000, Molbio Diagnostics Limited is a pioneer in the point-of-care (POC) molecular diagnostics space in India. Its flagship product, the 'Truenat' platform, is a battery-operated, portable real-time PCR system that performs automated sample preparation and analyzer functions, delivering results in under an hour even in resource-limited settings. The company has commercialized molecular testing for 30 diseases with 43 assays as of March 31, 2026, including tuberculosis, COVID-19, Hepatitis B/C, HIV, and HPV. Molbio relies heavily on public health programs, deriving 84.56% of its finished goods revenue in FY26 from Indian central/state governments and international aid agencies. The company's top ten customers, including the Central Medical Services Society, generated 83.26% of FY26 finished goods revenue. Molbio operates six manufacturing facilities in India (in Goa, Bengaluru, and Visakhapatnam) and is highly research-focused, conducting R&D through its wholly-owned subsidiary, Bigtec Private Limited. It also offers digital pathology, radiology, and breast health screening through subsidiaries like Prognosys and OptraScan. With institutional backing from Temasek and Motilal Oswal, the company has commercialized its products globally, exporting to more than 90 countries.

Truenat Devices — Refers to the sale of Truenat Platforms (workstations) comprising Trueprep and Truelab devices along with accessories such as printers and micropipettes. This segment generated ₹2,032.84 million, accounting for 14.06% of revenue from operations in FY26.
Truenat Test Kits — Refers to disease-specific, ready-to-use micro PCR chips, reagents, and cartridges. This segment is the core driver of recurring revenues, generating ₹10,348.20 million or 71.58% of revenue from operations in FY26, with tuberculosis tests contributing 70.20% of finished goods sales.
Other Products and Services — Includes radiology equipment (x-ray systems under Prognosys) and digital pathology solutions (digital pathology scanners under OptraScan), animal health screening, and other trading income.

Moat / Edge

Molbio has created a strong entry barrier and oligopolistic positioning with its 'Truenat' platform, which underwent 13 years of R&D to obtain ICMR certification. Its Truenat test chip for diagnosing TB is the only one developed by an Indian company (and one of only two globally) endorsed by the WHO for initial diagnosis and rifampicin resistance detection. The platform operates on a razor-and-blade model, generating high-margin, recurring revenues from proprietary disease-specific test kits that must be used with the device.

The Offer

Open – Close2026-08-10 – 2026-08-12

Price Band₹768–807

Lot Size18

Min Investment—

Issue Size₹940 cr

Fresh Issue₹200 cr

Offer for Sale—

ListingBSE

Follow the Money — Use of Proceeds

Funding capital expenditure towards the setting up of infrastructure for a research and development facility and Center of Excellence which will be operated by our wholly-owned Subsidiary, Bigtec, and connected office space for our Company, Subsidiaries and Associate — ₹105.54 cr
Funding capital expenditure towards the purchase of certain plant, machinery and other equipment for Goa Unit I, Goa Unit II and Visakhapatnam Unit — ₹72.28 cr
General corporate purposes

FinMinutes IPO Score — How It's Built

Transparent, deterministic, computed from the filing — not an opinion. Open any component below to see exactly what it measures, what it is worth, and where we are still using a neutral default rather than guessing. Weighted across 7 components.

Macro Timing 60/100

How this is measured6%

The market window around the issue date. This is currently a neutral placeholder: we have not yet wired it to index trend and recent listing performance, so it does not move the score in either direction.

Anchor Quality 50/100

How this is measured12%

Whether marquee anchor investors took part, and how many. Held at a neutral 50 when no marquee anchor is identified in the filing.

Issue Structure 70/100

How this is measured10%

Whether fresh capital actually enters the business. A predominantly offer-for-sale issue is marked down ONLY when the financials are weak. A profitable, cash-rich company selling down is treated as neutral, not penalised, because it does not need the money.

Financial Quality 80/100

How this is measured24%

Taken from the three-year numbers in the filing: whether the company was profitable in the latest year, and whether profit is rising or falling across the disclosed period.

Valuation Vs Peers 55/100

How this is measured16%

Where the multiples printed in the filing sit against the peer median. When the filing does not disclose comparable peer multiples, this is held at a neutral 55 rather than guessed.

Underwriter Quality 75/100

How this is measured14%

A proxy for syndicate strength, based today only on how many lead managers are on the issue. It sits at a neutral 60 unless three or more banks are involved. We have not yet built a bank-by-bank track record, so treat this as a rough signal.

Governance Forensics 52/100

How this is measured18%

Starts at 100 and loses points for every material red flag we find in the filing: contingent liabilities, related-party intensity, customer concentration, litigation, auditor qualifications. This is the component our DRHP forensics drives directly.

3-Year Financial & Growth Trend

Metric	FY26	FY25	FY24
Revenue (₹ Cr)	1445.687	1020.418	836.561
Net Profit (₹ Cr)	164.14	138.579	83.542
PAT Margin	11.35%	13.58%	9.99%

Revenue Breakdown

Revenue from sale of test kits: 71.58%
Revenue from sale of devices: 14.06%
Others (including subsidiary revenues and other operating revenues): 14.36%

Market Context

NOT part of the FinMinutes Score

The Score above is what the filing says. Everything in this box is what the crowd says. We keep them apart on purpose — every other site blends the two and calls the result a rating. Demand is real information, but it is information about the market, not about the company, and it changes by the hour while the company does not.

GMP₹180unofficial, grey market

Subscription is low early in a book and high at the end, because most bids arrive in the final hours. A number read on day one says more about the clock than the company — which is precisely why it is not in the Score. GMP is unofficial, unregulated, and easily moved. Neither is a recommendation.

Deep Financials

Revenue, EBITDA and profit are what every listing site prints. Below are the full restated statements as disclosed, the ratios we compute from them, and a DuPont decomposition of the return on equity. A prospectus carries three years, not ten — that is the document’s ceiling, and within it we go as deep as it allows.

Income StatementThe full profit and loss as restated in the filing.

Income Statement (₹ Cr)	FY26	FY25	FY24
Revenue from Operations	1,445.69	1,020.42	836.56
Other Income	9.48	7.52	4.10
Total Income	1,455.17	1,027.94	840.66
Cost of Materials Consumed	569.92	434.77	319.93
Employee Benefit Expense	145.23	102.79	63.89
Other Expenses	402.84	240.57	198.07
Total Expenses	1,221.35	820.41	657.83
EBITDA	328.24	256.64	185.09
Depreciation & Amortisation	63.64	44.55	41.01
EBIT	264.60	212.09	144.09
Finance Cost	33.47	17.66	14.45
Profit Before Tax	231.14	194.43	129.64
Tax Expense	67.00	55.85	46.10
Profit After Tax	164.14	138.58	83.54
EPS - Basic	14.77	12.87	9.05
EPS - Diluted	14.77	12.87	9.04

Balance SheetWhat the company owns, owes, and is worth on paper.

Balance Sheet (₹ Cr)	FY26	FY25	FY24
Share Capital	11.28	2.26	2.25
Reserves & Surplus	1,158.06	966.14	821.13
Net Worth	1,144.68	952.95	807.94
Long-term Borrowings	212.41	6.14	15.12
Short-term Borrowings	200.23	117.02	159.45
Total Borrowings	412.64	123.16	174.58
Trade Payables	199.50	230.21	93.99
Current Liabilities	557.36	441.67	342.76
Total Liabilities	839.65	494.27	392.22
Property, Plant & Equipment	248.08	204.06	167.91
Capital Work in Progress	11.32	27.33	1.58
Intangible Assets	170.81	52.78	70.42
Investments	5.98	45.57	5.99
Inventories	449.26	435.91	315.14
Trade Receivables	408.74	271.66	425.45
Cash & Equivalents	355.53	114.75	22.11
Current Assets	1,384.84	929.83	823.16
Total Assets	2,148.42	1,461.56	1,221.06

Cash FlowWhere the cash actually went. Often the most honest statement of the three.

Cash Flow (₹ Cr)	FY26	FY25	FY24
Net Cash from Operating Activities	50.39	287.10	9.57
Capital Expenditure	50.02	54.66	16.11
Net Cash from Investing Activities	-93.22	-122.65	-45.01
Net Cash from Financing Activities	276.07	-26.15	-31.55
Net Change in Cash	233.23	138.30	-66.99

Ratio AnalysisProfitability, leverage, liquidity, efficiency and earnings quality — computed by us.

Every ratio below is computed by us from the line items the company disclosed — not copied from anywhere. The arithmetic is standard; the point is that somebody actually did it. Blank cells mean the filing did not disclose the inputs, and we would rather show a gap than invent a number.

Ratio	FY26	FY25	FY24
Profitability
EBITDA Margin (%)	22.6	25	22
EBIT Margin (%)	18.2	20.6	17.1
PAT Margin (%)	11.4	13.6	10
Return on Equity (%)	14.3	14.5	10.3
Return on Capital Employed (%)	17	19.7	14.7
Return on Assets (%)	7.6	9.5	6.8
Leverage
Debt / Equity (x)	0.36	0.13	0.22
Net Debt / EBITDA (x)	0.17	0.03	0.82
Interest Coverage (x)	7.91	12.01	9.97
Liquidity
Current Ratio (x)	2.48	2.11	2.4
Quick Ratio (x)	1.68	1.12	1.48
Efficiency
Asset Turnover (x)	0.67	0.7	0.69
Receivable Days	103	97	186
Inventory Days	113	156	138
Payable Days	50	82	41
Cash Conversion Cycle (days)	166	171	283
Quality of Earnings
Operating Cash Flow / PAT (x)	0.31	2.07	0.11
Accruals Ratio (%)	5.3	-10.2	6.1
Capex / Depreciation (x)	0.79	1.23	0.39

DuPont DecompositionWhy the return on equity is what it is: margin, efficiency, or leverage.

A headline return on equity tells you what. The DuPont decomposition tells you why — whether the return is earned through margin, through asset efficiency, or simply through leverage. Two companies can post an identical ROE for opposite reasons, and only one of them is safe.

Component	FY26	FY25	FY24
Net Margin (PAT / Revenue)	11.4%	13.6%	10%
Asset Turnover (Revenue / Assets)	0.67x	0.7x	0.69x
Equity Multiplier (Assets / Net Worth)	1.88x	1.53x	1.51x
= Return on Equity	14.3%	14.5%	10.3%
Tax Burden (PAT / PBT)	0.71x	0.71x	0.64x
Interest Burden (PBT / EBIT)	0.87x	0.92x	0.9x
Operating Margin (EBIT / Revenue)	18.3%	20.8%	17.2%

Computed from the disclosed statements. Where the filing omits an input, the row is left blank rather than estimated.

Quality of EarningsWhat the statements say when you read them against each other.

What the statements say once you read them against each other. These are observations, not verdicts — every one is arithmetic on the numbers the company itself disclosed, and each is stated so you can go and check it in the filing.

Operating cash flow was only 0.31x reported profit in FY26. Less than half of the profit on the income statement arrived as cash.
Receivable days fell from 186 to 103. Collections improved over the disclosed period.

Forensic ModelsBeneish, Altman and Piotroski — plus our own final-year check.

Beneish M-Score

M = -1.89

An eight-variable model built to detect earnings manipulation, and built to run on exactly two consecutive years — which is what a prospectus gives us. It belongs here more than anywhere: a company about to list has the maximum possible incentive to have dressed up the very years it is about to show you. A score above −1.78 is the threshold at which the model says the accounts merit a closer look. It is a screening signal, not an accusation, and it was calibrated on listed companies elsewhere. Read the eight components, not just the total.

Component	Value	What it captures
DSRI Days Sales in Receivables Index `(Receivables_t / Sales_t) / (Receivables_t-1 / Sales_t-1)`	1.062	Above 1 means receivables grew faster than sales. Revenue may be being recognised ahead of collection.
GMI Gross Margin Index `GrossMargin_t-1 / GrossMargin_t`	0.947	Above 1 means margins deteriorated. A firm with worsening prospects has more incentive to manipulate.
AQI Asset Quality Index `AQ_t / AQ_t-1, where AQ = 1 - (CurrentAssets + PPE) / TotalAssets`	1.07	Above 1 means a rising share of assets is soft (neither current nor fixed) — capitalised costs can hide here.
SGI Sales Growth Index `Sales_t / Sales_t-1`	1.417	Growth is not manipulation. But high-growth firms face more pressure to keep the streak going.
DEPI Depreciation Index `DepRate_t-1 / DepRate_t, where DepRate = Dep / (Dep + PPE)`	0.878	Above 1 means assets are being depreciated more slowly — a quiet way to lift reported profit.
SGAI SG&A Index `(SGA_t / Sales_t) / (SGA_t-1 / Sales_t-1), SGA proxied as employee cost + other expenses`	1.127	A proxy, because filings rarely break out SG&A cleanly. Read it as a direction, not a precise figure.
LVGI Leverage Index `Leverage_t / Leverage_t-1, where Leverage = (CurrentLiab + LongTermDebt) / TotalAssets`	1.169	Above 1 means leverage rose. Debt covenants create pressure to hit numbers.
TATA Total Accruals to Total Assets `(PAT - CashFromOperations) / TotalAssets`	0.0529	The gap between reported profit and cash generated. The single heaviest term in the model — and the one that catches profit that never became cash.

M = -1.89, below the −1.78 threshold. The model does not flag these accounts.

Altman Z″-Score (emerging markets)

Z″ = 9.79 · Safe

A distress-prediction model. We use the Z″ variant deliberately: the original Z was calibrated on American manufacturers and misleads badly on Indian services companies. Above 2.6 is the safe zone, 1.1 to 2.6 is grey, below 1.1 is the distress zone. Like every model of its kind it is a screen, not a prophecy.

X1 — Working Capital / Total Assets	0.385
X2 — Retained Earnings / Total Assets	0.539
X3 — EBIT / Total Assets	0.123
X4 — Net Worth / Total Liabilities	1.363
Z″ = 3.25 + 6.56·X1 + 3.26·X2 + 6.72·X3 + 1.05·X4	9.79

Piotroski F-Score (adapted)

4 / 8

Nine yes-or-no tests of fundamental strength — except we run eight. One of the original nine asks whether the company issued new shares, which is plainly absurd to ask of a company whose entire purpose at this moment is to issue shares. We drop that test and score out of eight, and we would rather tell you that than quietly fudge it.

✓Positive return on assets
✓Positive operating cash flow
✗Return on assets improving
✗Cash flow exceeds profit (quality of earnings)
✗Long-term leverage decreasing
✓Current ratio improving
✓Gross margin improving
✗Asset turnover improving

The Final-Year Check

ours

Not from any textbook. The hockey stick in the last year before a filing is the oldest pattern in this business, and nobody publishes it. So we measure it: how the final disclosed year compares with the years behind it. Real acceleration looks exactly the same on the page as a flattering one — which is precisely why it is worth naming rather than assuming either way.

Cash conversion fell sharply in the final year: operating cash flow was 0.31x profit in FY26, against 2.07x in FY25. Profit rose; the cash behind it did not follow at the same rate.

Ratios Nobody Prints

Contingent liabilities / Net worth: 14.7%
Contingent liabilities of 168.74 cr against a net worth of 1,144.68 cr — 14.7% of what the company is worth on paper. These are obligations that sit off the balance sheet but could land on it. What they consist of matters as much as the size: a corporate guarantee to a subsidiary is a different animal from a disputed tax demand, and the filing says which.
Cash / Short-term borrowings: 1.78x
Short-term borrowings of 200.23 cr against cash of 355.53 cr. Debt that must be refinanced within a year is only comfortable while lenders stay comfortable.
Promoter remuneration / PAT: 6.4%
Managerial remuneration to the promoter group was 10.49 cr against a profit of 164.14 cr. This is a legitimate cost — but it is also a route by which value leaves a company before it ever reaches a minority shareholder.

The Formula NotebookEvery number above, with the working shown. Check us.

Every number we publish, with the working shown. The formula, the same formula with this company’s actual figures put into it, the answer, and what it is for. Check us. That is the point.

Profitability

Return on Equity (ROE)14.3%

FormulaPAT ÷ Net Worth

Worked164.14 ÷ 1,144.68

What the company earned on the money shareholders have in it. The headline measure of return — and the one the DuPont section takes apart.

Return on Capital Employed (ROCE)17%

FormulaEBIT ÷ (Net Worth + Total Borrowings)

Worked264.60 ÷ (1,144.68 + 412.64) = 264.60 ÷ 1,557.31

Return on ALL the capital in the business, borrowed as well as owned. Unlike ROE, it cannot be flattered by taking on debt.

EBITDA Margin22.6%

FormulaEBITDA ÷ Revenue

Worked328.24 ÷ 1,445.69

Operating profitability before the effects of debt, tax and depreciation. What the business earns from the act of trading.

Leverage

Debt to Equity0.36x

FormulaTotal Borrowings ÷ Net Worth

Worked412.64 ÷ 1,144.68

How much the company has borrowed against what it owns. High is not automatically bad — ask whether the borrowing is being serviced comfortably.

Interest Coverage7.91x

FormulaEBIT ÷ Finance Cost

Worked264.60 ÷ 33.47

How many times over operating profit covers the interest bill. Below about 2x, a meaningful share of what the business earns is going to lenders rather than owners.

Efficiency

Receivable Days103 days

Formula(Trade Receivables ÷ Revenue) × 365

Worked(408.74 ÷ 1,445.69) × 365

How long the company waits to be paid. Rising receivable days mean revenue is being booked faster than it is collected — which is where a great many accounting problems begin.

Cash Conversion Cycle166 days

FormulaInventory Days + Receivable Days − Payable Days

Worked113 + 103 − 50

How long cash is tied up in the operating cycle before it comes back. The longer it is, the more working capital the business must fund.

Quality of Earnings

Operating Cash Flow to Profit0.31x

FormulaCash from Operations ÷ PAT

Worked50.39 ÷ 164.14

Did the profit turn into cash? Profit is an opinion; cash is a fact. When this sits well below 1x for long, the two are drifting apart, and the filing is where you find out why.

Accruals Ratio5.3%

Formula(PAT − Cash from Operations) ÷ Total Assets

Worked(164.14 − 50.39) ÷ 2,148.42 = 113.76 ÷ 2,148.42

The share of reported profit that exists on paper rather than in the bank. It is also the heaviest single term in the Beneish model, for good reason.

Institutional Alpha: DRHP Deep Dive

Industry Overview (RHP p. 175, 215, 219)

According to the 1Lattice Report, the global point-of-care testing (POCT) market is experiencing rapid expansion, driven by the increasing relevance of near-patient diagnostics, which offer faster turnaround times, lower capital costs, and ease of use in resource-limited or decentralized settings. Electrification and battery operation are crucial for penetration in emerging economies. Molecular diagnostics represents a highly competitive yet high-barrier space characterized by intensive R&D, stringent regulatory clearances (such as ICMR and WHO), and oligopolistic structures. Key growth areas include infectious disease screening (such as TB and COVID-19) and non-communicable diseases. Established players with strong technological IP, razor-and-blade recurring revenue profiles, and validated manufacturing capabilities are well-positioned to capitalize on this shift from centralized laboratory testing.

Market SizeUSD 29.3 billion (equivalent to ₹ 2,588.6 billion) (Global POCT Market) Growth17.9% CAGR between 2025 and 2030

Future Planning & Capital Allocation

The company’s capital allocation strategy focuses heavily on long-term capabilities rather than immediate capacity. It allocates ₹105.54 crore of its Fresh Issue proceeds for setting up research and development infrastructure and a Center of Excellence through subsidiary Bigtec, alongside ₹72.28 crore for procurement of plant and machinery to expand and automate facilities in Goa and Visakhapatnam.

Source: RHP p. 37, 128-129

Competitive Position

Molbio holds an oligopolistic competitive position secured by WHO and ICMR approvals for molecular diagnostics. Being one of only two globally approved point-of-care TB diagnostic platforms provides immense pricing power and bidding advantages in public tender programs.

Source: RHP p. 142, 215, 219

Execution / Track Record

The company has demonstrated robust growth, scaling consolidated revenue from operations from ₹836.56 crore in FY24 to ₹1,445.69 crore in FY26. Concurrently, test kit volumes scaled from 8.80 million to 17.56 million, proving strong commercialization traction.

Source: RHP p. 79, 315-316, 375

Shareholding, Syndicate & Leadership

Promoter Pre → Post46.65% → —%

Pledged Shares0%

Free Float—%

Anchor—

Merchant Bankers (BRLMs)Kotak Mahindra Capital Company Limited, IIFL Capital Services Limited (formerly known as IIFL Securities Limited), Jefferies India Private Limited, Motilal Oswal Investment Advisors Limited

RegistrarKFin Technologies Limited

Leadership & Skin in the Game

Leadership: Sriram Natarajan

Litigation: Outstanding tax claims against the Company total 11 cases involving an aggregate disputed amount of ₹507.81 million (comprising ₹235.02 million in direct taxes and ₹272.79 million in indirect taxes). In addition, Promoter Sriram Natarajan has 1 pending direct tax dispute involving ₹46.03 million. Pending criminal proceedings filed by the Company and its subsidiaries total ₹188.89 million.

Auditor / RPT Flags: Statutory auditors included emphasis of matter paragraphs regarding a ₹199.00 million EMD fraud in subsidiary Prognosys Medical Systems and audit modifications/qualifications regarding unenabled database-level audit trails, disabled edit logs, and missing daily offsite server backups of electronic books of account. Significant related party transactions include a ₹1,233.62 million royalty expense paid to Bigtec Private Limited in FY26.

Peers & Valuation

Company	P/E	P/B	RoE	Margin
Poly Medicure Limited	52.61	—	10.37	—
Dr. Lal Pathlabs Limited	62.2	—	20.78	—
Metropolis Healthcare Limited	63.72	—	12.56	—
Vijaya Diagnostics Centre Limited	81.02	—	18.07	—

🔍 Forensic Findings — What the Footnotes Say

Risks hiding outside the risk section — mined from MD&A, related-party notes, contingent liabilities and litigation. This is the FinMinutes edge.

Audit Trail (Edit Log) Gaps and Backup Failures where: footnotes flagged

Statutory auditors reported that the audit trail (edit log) feature in core accounting software was not enabled at the database level or for certain transactions, and records were not preserved for prior years. In addition, backup of books of accounts in electronic mode was not maintained on servers physically located in India on a daily basis for certain periods.

RHP p. 419, 420, 422, 428, 782, 784

Intermediary Fund Routing where: footnotes flagged

Statutory auditors noted that in FY24, the Group advanced ₹60.00 million to Chayagraphics (India) Private Limited, which acted as an intermediary to further advance ₹58.62 million to the ultimate beneficiary (a shareholder of Chayagraphics Healthcare Private Limited).

RHP p. 422, 502, 724, 725, 785

Discrepancies in Bank Stock and Debt Statements where: footnotes flagged

The quarterly returns comprising stock and book debt statements filed by the Company and its subsidiary (Prognosys Medical Systems) with banks cannot be reconciled with audited/reviewed books of account or are not in agreement with books of account due to timing differences in passing entries.

RHP p. 507, 517, 518, 563, 564, 786, 790, 795

Multiple Prior Employee and Vendor Frauds where: other flagged

The statutory reports highlight that (i) two external parties misappropriated ₹4.43 million from the Company in FY25; (ii) an employee of Bigtec misappropriated ₹6.09 million in FY24 via unauthorized payments for fake/inflated purchase orders; and (ii) subsidiary Prognosys Medical Systems suffered a ₹199.00 million fraud regarding misappropriation of earnest money deposits (EMD) prior to acquisition.

RHP p. 36, 109, 110, 417, 779, 792, 797

Government and Aid Agency Revenue Concentration where: risk_section noted

The company derives a substantial portion of finished goods contract revenues from public healthcare programs of Indian central/state governments and international aid agencies, contributing 84.56% in FY26, 87.83% in FY25, and 91.60% in FY24.

RHP p. 28, 368

Material Uncertainty Over Subsidiary Financial Viability where: footnotes noted

Statutory auditors reported that material uncertainty exists regarding the capability of subsidiaries Prognosys Medical Systems and Prognosys Healthcare (India) to meet their liabilities as they fall due within one year.

RHP p. 524, 526, 540, 541, 789, 793, 798

Material Litigation where: litigation flagged

Outstanding tax claims against the Company total 11 cases involving an aggregate disputed amount of ₹507.81 million (comprising ₹235.02 million in direct taxes and ₹272.79 million in indirect taxes). In addition, Promoter Sriram Natarajan has 1 pending direct tax dispute involving ₹46.03 million. Pending criminal proceedings filed by the Company and its subsidiaries total ₹188.89 million.

RHP p. 22, 28, 36, 62, 84, 88, 101, 110, 137, 417, 419, 420, 422, 425, 426, 428, 803, 828, 836

Auditor / RPT Notes where: rpt noted

Statutory auditors included emphasis of matter paragraphs regarding a ₹199.00 million EMD fraud in subsidiary Prognosys Medical Systems and audit modifications/qualifications regarding unenabled database-level audit trails, disabled edit logs, and missing daily offsite server backups of electronic books of account. Significant related party transactions include a ₹1,233.62 million royalty expense paid to Bigtec Private Limited in FY26.

RHP p. 22, 28, 36, 62, 84, 88, 101, 110, 137, 417, 419, 420, 422, 425, 426, 428, 803, 828, 836

Company's Claims vs Reality

We stress-test each claim against the filing's own data.

We have a scalable business model with strong entry barriers and a high proportion of recurring revenues driven by our Truenat molecular diagnostic platform. Supported

Do restated financials and sales volumes verify a highly recurring razor-and-blade model?

RHP p. 218, 315, 375 (Revenues from sale of test kits scaled to ₹10,348.20 million or 71.58% of FY26 operations, driven by 17.56 million kits sold, whereas device sales were ₹2,032.84 million, supporting a highly recurring blade revenue structure)

The company possesses strong entry barriers based on R&D focus and unique regulatory/WHO clearances. Supported

Does independent industry research confirm the exclusivity of the WHO clearances?

RHP p. 142, 215, 219 (Our Truenat test chip is the only molecular test developed by an Indian company, and one of only two globally, endorsed by the WHO for initial diagnosis of TB and rifampicin resistance, which was obtained after 13 years of R&D)

Proprietary SWOT — Company-Specific

Strengths

WHO-endorsed flagship Truenat PCR platform, representing a critical, highly validated tool for global tuberculosis screening.
Highly cash-generative razor-and-blade model with test kits driving 71.58% of consolidated operating revenues in FY26.

Weaknesses

Extreme reliance on public health channels, with 84.56% of finished goods revenue tied to government programs and international aid agencies.
Underperforming subsidiaries including OptraScan INC and Prognosys Healthcare which incurred net losses in FY26.

Opportunities

Substantial test menu expansion, with plans to launch 34 additional assays for 22 diseases.
Strategic entry into highly regulated overseas markets, particularly Western Europe and the United States.

Threats (material, not boilerplate)

Changes in government funding or policy priorities for public health programs. risk_section
Why it matters: Because 84.56% of finished goods revenue is government-dependent, any funding freeze or budget realignment directly impacts product sales.
Significant cash flow impact from pending direct and indirect tax disputes totaling ₹507.81 million. litigation
Why it matters: An adverse final ruling in these tax proceedings would require substantial cash outflows, impacting liquidity.

Analyst Q&A: Burning Questions

Facts from the filing. No recommendation — that layer arrives once our Research Analyst registration is live.

USE OF PROCEEDS

Where is the money going?

The Net Proceeds from the ₹200.00 crore Fresh Issue are being deployed towards capital expenditure. Specifically, ₹105.54 crore is allocated for setting up research and development infrastructure and a Center of Excellence for wholly-owned subsidiary Bigtec, and ₹72.28 crore is earmarked for purchasing plant, machinery, and automation equipment for manufacturing units in Goa and Visakhapatnam.

RHP p. 37, 128-129

CONCENTRATION

How concentrated is the customer base?

The customer base is highly concentrated. The top 10 customers contributed 83.26% of finished goods sales in FY26 (compared to 83.62% in FY25 and 78.54% in FY24). Additionally, finished goods sales to central/state government healthcare programs and international aid agencies represented 84.56% of total contract sales in FY26.

RHP p. 28, 368

PROFITABILITY

Is it profitable and growing?

Yes. Revenue from operations increased from ₹836.56 crore in FY24 to ₹1,020.42 crore in FY25, and scaled to ₹1,445.69 crore in FY26. Consolidated net profit (PAT) was ₹83.54 crore in FY24, ₹138.58 crore in FY25, and ₹164.14 crore in FY26, maintaining an EBITDA margin of 22.56% in FY26.

RHP p. 79, 316, 371

HIDDEN RISKS

What sits in the footnotes / contingent liabilities?

As of March 31, 2026, contingent liabilities total ₹1,687.42 million (comprising bank guarantees of ₹900.98 million, direct tax disputes of ₹461.48 million, indirect tax disputes of ₹322.37 million, and other claims of ₹2.59 million). Footnotes also disclose outstanding Income Tax department demands of ₹234.17 million following a survey under Section 133A, along with recurring statutory auditor exceptions regarding unenabled database-level audit trails and missing daily local server backups.

RHP p. 62, 84, 175, 419, 420, 425, 426, 428, 782, 803

GMP: ₹180 — unofficial grey-market chatter, shown for information only. Never part of the FinMinutes Score.

What Earlier Investors Paid

Early capital takes real risk and is fairly rewarded for it — a large multiple built over many years is normal. What deserves a closer look is a steep step-up in a short window: a round priced cheaply only months before the offer.

Shareholder	Priced at	When	vs IPO price
Shankar Gopalkrishnan	₹651.46	2024-09-03	1.2x
The 3 allotments below are shown at their as-disclosed per-share price. These prices are not adjusted for any later bonus issue or share split, so where the company has issued bonus shares the raw multiple understates the true return and can even read as a loss when none was made. We show them as filed and decline to compute a misleading multiple. Bonus-adjusted cost is on the roadmap.
India Business Excellence Fund III	₹7,248.70	2021-05-31	as disclosed
India Business Excellence Fund III	₹7,248.70	2021-05-31	as disclosed
V Sciences Investments Pte. Ltd.	₹54,495.91	2022-09-23	as disclosed

Prices are as stated in the filing’s allotment history and are not adjusted for later bonus issues or share splits. Where a company has issued bonus shares, the multiples above understate the true return and can even read as losses. Adjusting for that is on our list; until it is done we would rather show the raw disclosure and tell you its limits than publish a confident number that is wrong.

Lock-in Expiry Calendar

Shares held before the IPO cannot be sold immediately; they unlock in tranches. When a tranche unlocks, more shares become eligible to trade. Retail investors are frequently caught unaware by these dates. The schedule below follows from the listing date; quantities are shown only where the filing discloses them.

17 Aug 2029
Minimum Promoters' Contributionthree years
17 Aug 2027
Promoters' shareholding in excess of Minimum Promoters' Contributionone year
17 Feb 2027
Entire pre-Offer equity share capitalsix months
15 Nov 2026
Anchor Investors (50%)90 days
16 Sep 2026
Anchor Investors (50%)30 days

An unlock means more shares may be sold — not that they will be, and not that the price will move. We state the dates; what you do with them is your call.

What Changed Between the DRHP and the RHP

Companies file a draft prospectus, then a final one. The changes in between are rarely reported, and they can be revealing.

Item	In the DRHP	In the RHP / Addendum
Offer for Sale (OFS) Share Volume The Offer for Sale size was reduced by 3,390,000 Equity Shares (representing a 27.00% reduction), while the Fresh Issue component remained unchanged at up to ₹ 2,000.00 million.	Up to 12,556,000 Equity Shares	Up to 9,166,000 Equity Shares
Financial Information Period The financial disclosures were rolled forward to include full Fiscal 2026 financials, dropping the oldest reporting year (Fiscal 2023).	Restated Consolidated Summary Statements for Fiscals 2025, 2024 and 2023	Restated Consolidated Summary Statements for Fiscals 2026, 2025 and 2024
Chief Financial Officer The company appointed Manan Bimal Khokhani as the new Chief Financial Officer, replacing Amol Narayan Lone, effective December 22, 2025.	Amol Narayan Lone	Manan Bimal Khokhani
Use of Proceeds (CAPEX for R&D facility and Center of Excellence) The proposed allocation from Net Proceeds for setting up the R&D facility and Center of Excellence was increased by ₹ 61.67 million.	Up to ₹ 993.68 million	Up to ₹ 1,055.35 million
Weighted Average Cost of Acquisition (WACA) in preceding 1 Year The weighted average cost of acquisition of shares transacted in the 1 year preceding the prospectus increased from ₹ 1,042.95 to ₹ 1,090.00, reflecting secondary transactions executed up to October 4, 2025.	₹ 1,042.95 per share	₹ 1,090.00 per share

Educational, grounded entirely in the company's filings (DRHP/RHP). Not investment advice. FinMinutes does not provide buy/sell recommendations.